Lipigon Pharmaceuticals AB

Lipigon Pharmaceuticals is a Swedish pharma company founded in 2010 and based on 50+ years of lipid metabolism research at Umeå University. Develops novel therapies for lipid metabolism disorders. Lead candidate Lipisense (RNA drug) is in Phase I for hypertriglyceridemia. Pipeline also includes candidates for ARDS, lipodystrophy (with Combigene) and dyslipidemia (with HitGen). Listed on Nasdaq First North (LPGO).